Enliven Therapeutics Inc. (ELVN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.50B
Last updated: Nov 17, 2026 at 4:15 PM ET
Enliven Therapeutics Inc. (ELVN) Statistics
Enliven Therapeutics (ELVN) has a market cap of $3.50B and an enterprise value of $3.35B. Its share count is up 25.59% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 4.33% below the market cap, as cash exceeds debt.
| Market Cap | $3.50B |
|---|---|
| Enterprise Value | $3.35B |
| Latest price (Nov 17, 2026) | $46.85 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 112.28% over 52 weeks and trades 1.96% above its 50-day average.
| Beta (1Y) | 1.12 |
|---|---|
| 52-Week Change | +112.28% |
| 1-Month Change | +21.06% |
| 3-Month Change | -21.11% |
| 6-Month Change | +16.63% |
| 5-Year Change | +207.29% |
| Total Return (1Y) | +112.28% |
| Total Return (3Y CAGR) | +65.14% |
| Total Return (5Y CAGR) | +28.47% |
| Return vs SPY (1Y) | +95.83% |
| Max Drawdown (1Y) | -38.97% |
| Max Drawdown (3Y) | -49.54% |
| Sharpe Ratio (1Y) | 1.03 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $45.95 |
| 200-Day Average | $44.03 |
| 52-Week Range | $14.79 to $62.32 |
| RSI (14 Days) | 51.1 |
| Average Volume (20 Days) | 1.50M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 45.95x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 45.95x |
|---|---|
| Quick Ratio | 45.95x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -12.94% and return on assets is -12.65% over the last 12 months.
| Return on Equity (ROE) | -12.94% |
|---|---|
| Return on Assets (ROA) | -12.65% |
| ROA (5Y Average) | -35.10% |
| ROIC (5Y Average) | -20.58% |
Scores
ELVN has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$46.00K |
| Operating Income | -$135.36M |
| Pretax Income | -$113.48M |
| Net Income | -$113.48M |
| Reported EPS (TTM) | -$1.71 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 97.74% of the $897.23M in total assets.
| Cash and Equivalents | $151.67M |
|---|---|
| Total Debt | $0 |
| Net Cash | $151.67M |
| Net Cash Per Share | $1.94 |
| Working Capital | $875.28M |
| Shareholder Equity | $876.95M |
| Book Value Per Share | $11.25 |
| Total Assets | $897.23M |
| Total Liabilities | $20.28M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $193.00K of capital spending, operating cash flow left -$66.41M of free cash flow.
| Operating Cash Flow | -$66.22M |
|---|---|
| Capital Expenditures | $193.00K |
| Free Cash Flow | -$66.41M |
| FCF Per Share | -$0.91 |
| Depreciation and Amortization | $1.98M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +16.47% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +16.47% |
Dividends and Yields
ELVN does not pay a dividend. Its free cash flow yield is -1.82%.
| FCF Yield | -1.82% |
|---|---|
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.01% |
Stock Splits
The last split was a 1-for-4 reverse split on Feb 24, 2023.
| Last Split Date | Feb 24, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:4 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ELVN
What is ELVN's market cap?
Enliven Therapeutics has a market cap of $3.50B. Its enterprise value, which adds debt and subtracts cash, is $3.35B.
How many shares of ELVN are outstanding?
Enliven Therapeutics has 77.98M shares outstanding. The count is up 25.59% from a year earlier.
Does ELVN pay a dividend?
No. Enliven Therapeutics does not pay a dividend.
How much debt does ELVN have?
Enliven Therapeutics has $0 of total debt and $151.67M of cash and equivalents, a net cash position of $151.67M.
ELVN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors